(Q37221785)

19 August 2017

title

DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients? (English)

1 reference

19 August 2017

S Halimi

1

1 reference

19 August 2017

publication date

1 February 2008

1 reference

19 August 2017

published in

Diabetes and Metabolism

1 reference

19 August 2017

volume

34 Suppl 2

1 reference

19 August 2017

page(s)

S91-5

1 reference

Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973400-1

7 January 2021

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973400-1

7 January 2021

Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973400-1

7 January 2021

Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973400-1

7 January 2021

Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973400-1

7 January 2021

Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973400-1

7 January 2021

Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973400-1

7 January 2021

Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973400-1

7 January 2021

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973400-1

7 January 2021

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973400-1

7 January 2021

Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973400-1

7 January 2021

Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973400-1

7 January 2021

Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973400-1

7 January 2021

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973400-1

7 January 2021

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973400-1

7 January 2021

Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973400-1

7 January 2021

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973400-1

7 January 2021

Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973400-1

7 January 2021

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973400-1

7 January 2021

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973400-1

7 January 2021

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973400-1

7 January 2021

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973400-1

7 January 2021

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973400-1

7 January 2021

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973400-1

7 January 2021

Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973400-1

7 January 2021

10.1016/S1262-3636(08)73400-1

Identifiers

DOI

1 reference

19 August 2017

1 reference